Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa
Ronan A. Murphy, Matthew Coates, Sophia Thrane, Akshay Sabnis, James Harrison, Silke Schelenz, Andrew M. Edwards, Thomas Vorup‐Jensen, Jane C. Davies
Abstract
than predicted for their combination. As a peptide drug, glatiramer acetate functions similarly to many antimicrobial peptides, interacting with and disrupting the P. aeruginosa cell wall and permeabilizing bacterial cells, thereby allowing tobramycin to work. Our findings demonstrate that glatiramer acetate is a strong candidate for repurposing as an antibiotic resistance breaker of pathogenic P. aeruginosa.
Topics & Concepts
TobramycinPseudomonas aeruginosaCystic fibrosisGlatiramer acetateDrugPharmacologyPeptideMedicineMicrobiologyChemistryInternal medicineBiologyBacteriaBiochemistryDiseaseGeneticsAntimicrobial Peptides and ActivitiesCystic Fibrosis Research AdvancesAntibiotic Resistance in Bacteria